Agent (target) | Tumor type | Treated patients(n) | Patients, n (%) | Reference | ||||
Pneumonia | Pneumonia-associated death | All-grade pneumonitis | Pneumonitis-associated death | ARDS | ||||
Nivolumab (PD-1) | Melanoma | 313 | 2 (0.6%) | NA | 5 (1.6%) | NA | NA | Hodi FS, et al. Lancet Oncol 2018;19:1480–92. |
206 | NA | NA | 3 (1.5%) | NA | NA | Robert C, et al. N Engl J Med 2015;372:320–30. | ||
268 | NA | NA | 5 (1.9%) | NA | NA | Weber JS, et al. Lancet Oncol 2015;16:375–84. | ||
NSCLC | 287 | 17 (5.9%) | NA | 8 (2.8%) | NA | NA | Borghaei H, et al. N Engl J Med 2015; 373:1627–39. | |
391 | NA | NA | 9 (2.3%) | 1 (0.3%) | NA | Hellmann MD, et al. N Engl J Med 2018;378:2093–104. | ||
131 | NA | NA | 6 (4.6%) | NA | NA | Brahmer J, et al. N Engl J Med 2015;373:123–35. | ||
HNSCC | 236 | 10 (4.2%) | NA | 5 (2.1%) | 1 (0.4%) | NA | Ferris RL, et al. N Engl J Med 2016;375:1856–67. | |
Pembrolizumab (PD-1) | Melanoma | 277 | NA | NA | 5 (1.8%) | NA | NA | Robert C, et al. N Engl J Med 2015;372:2521–32. |
357 | NA | NA | 3 (0.8%) | NA | NA | Ribas A, et al. Lancet Oncol 2015;16:908–18. | ||
277 | NA | NA | 3 (1.1%) | NA | NA | Schachter J, et al. Lancet 2017;390:1853–62. | ||
NSCLC | 339 | 5 (1.5%) | 1 (0.3%) | 16 (4.7%) | 2 (0.6%) | NA | Herbst RS, et al. Lancet 2016;387:1540–50. | |
636 | NA | NA | 43 (6.8%) | 1 (0.2%) | NA | Mok TSK, et al. Lancet 2019;393:1819–30. | ||
550 | NA | NA | 10 (1.8%) | NA | NA | Leigh NB, et al. Lancet Respir Med 2019;7:347–57. | ||
154 | NA | NA | 12 (7.8%) | 1 (0.6%) | NA | Reck M, et al. J Clin Oncol 2019;37:537–46. | ||
154 | NA | NA | 9 (5.8%) | NA | NA | Reck M, et al. N Engl J Med 2016;375:1823–33. | ||
Urothelial Cancer | 370 | 1 (0.3%) | 1 (0.3%) | 5 (1.4%) | NA | NA | Balar AV, et al. Lancet Oncol 2017;18:1483–92. | |
Urothelial carcinoma | 266 | NA | NA | 11 (4.1%) | 1 (0.4%) | NA | Bellmunt J, et al. N Engl J Med 2017;376:1015–26. | |
Gastric cancer | 294 | NA | NA | 8 (2.7%) | NA | NA | Shitara K, et al. Lancet 2018;392:123–33. | |
Atezolizumab (PD-L1) | NSCLC | 142 | 4 (3%) | NA | 4 (3%) | NA | NA | Fehrenbacher L, et al. Lancet 2016;387:1837–46. |
609 | NA | NA | 6 (1%) | NA | NA | Rittmeyer A, et al. Lancet 2017;389:255–65. | ||
Ipilimumab (CTLA-4) | Melanoma | 311 | NA | NA | 5 (1.6%) | NA | NA | Hodi FS, et al. Lancet Oncol 2018;19:1480–92. |
256 | NA | NA | 1 (0.4%) | NA | NA | Robert C, et al. N Engl J Med 2015;372:2521–32. | ||
Prostate cancer | 393 | 24 (6%) | 1 (0.3%) | 5 (1.3%) | NA | NA | Kwon ED, et al. Lancet Oncol 2014;15:700–12. | |
Tremelimumab (CTLA-4) | Malignant mesothelioma | 380 | 18 (4.7%) | 1 (0.3%) | 3 (0.8%) | NA | 1 (0.3%) | Maio M, et al. Lancet Oncol 2017;18:1261–73. |
Melanoma | 325 | 1 (0.3%) | 1 (0.3%) | NA | NA | NA | Ribas A, et al. J Clin Oncol 2013;31:616–22. | |
Ipilimumab+nivolumab (CTLA-4+PD-1) | Melanoma | 313 | NA | NA | 23 (7.3%) | NA | NA | Hodi FS, et al. Lancet Oncol 2018;19:1480–92 |
313 | NA | NA | 22 (7%) | NA | NA | Wolchok JD, et al. N Engl J Med 2017;377:1345–56. | ||
94 | 1 (1%) | NA | 9 (10%) | 1 (1%) | NA | Hodi FS, et al. Lancet Oncol 2016;17:1558–68. | ||
NSCLC | 39 | 1 (2.6%) | NA | 2 (5.1%) | NA | NA | Hellmann MD, et al. Lancet Oncol 2017;18:31–41. | |
576 | NA | NA | 22 (3.8%) | 3 (0.5%) | NA | Hellmann MD, et al. N Engl J Med 2018;378:2093–104. | ||
SCLC | 61 | NA | NA | 2 (3.2%) | NA | NA | Antonia SJ, et al. Lancet Oncol 2016;17:883–95. |
ARDS, acute respiratory distress syndrome; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; HNSCC, head and neck squamous cell carcinoma; ICI, immune checkpoint inhibitor; NA, not applicable; NSCLC, non-small cell lung cancer; PD-1, programmed death 1; PD-L1, programmed death-ligand 1; SCLC, small cell lung cancer.